S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
Did You Get Your Free Bitcoin Yet? (Ad)
Stock market today: Tumbling tech stocks drag Wall Street to the finish line of another losing week
American Express profits jump 34%, helped by jump in new customers, higher spending
Tiny Biotech Stock Wins $75 Billion Patent (Ad)
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
The Best AI Stock to Own in the World Today is Trading for Just $25 (Ad)
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Free Trial
NASDAQ:AERI

Aerie Pharmaceuticals (AERI) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)
Free AERI Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$15.25
▼
$15.25
50-Day Range
$15.18
▼
$15.25
52-Week Range
$4.81
▼
$15.37
Volume
600 shs
Average Volume
974,748 shs
Market Capitalization
$753.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
AERI stock logo

About Aerie Pharmaceuticals Stock (NASDAQ:AERI)

Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma or ocular hypertension. The company also develops AR-15512 to treat signs and symptoms of dry eye; and AR-1105 and AR-14034 SR sustained-release implants focused on retinal diseases. It has a collaborative research, development, and licensing agreement with DSM Biomedical. Aerie Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Durham, North Carolina.

AERI Stock News Headlines

February 29, 2024 | uk.finance.yahoo.com
20 Countries With Worst Vision Problems
February 21, 2024 | finance.yahoo.com
Paratus Sciences Appoints Theresa Heah, M.D., M.B.A. as Chief Executive Officer
April 19, 2024 | Altimetry (Ad)
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
January 12, 2024 | msn.com
Justin Timberlake is ready to Rock Your Body for one night only in Memphis, and for free
January 10, 2024 | msn.com
Alcon’s dry eye drug achieves primary endpoints in Phase III trials
January 8, 2024 | finanznachrichten.de
Curative Biotechnology, Inc.: Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
January 8, 2024 | markets.businessinsider.com
Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors
December 15, 2023 | finance.yahoo.com
Glaucoma Therapeutics Market Size Projected to Reach USD 13.5 billion by 2031, With 5.5% CAGR: Transparency Market Research, Inc.
April 19, 2024 | Altimetry (Ad)
Secret Bull Market Starts in This Unusual Sector
"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.
November 28, 2023 | finance.yahoo.com
Global Over the Counter (OTC) Drugs Market Size to Grow USD 265 Billion by 2032 | CAGR of 5.0%
November 25, 2023 | nypost.com
Aerie’s Black Friday Sale is here —Save 40% off sitewide for a limited time
November 23, 2023 | finance.yahoo.com
Netarsudil for Fuchs Endothelial Corneal Dystrophy (FECD), 2019-2023 Emerging Drug Insights and Forecasts to 2032
November 23, 2023 | finance.yahoo.com
Global Glaucoma Treatment Market Size To Grow USD 10.5 Billion by 2032 | CAGR of 5.0%
October 27, 2023 | finanznachrichten.de
Opthea Limited: Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
October 27, 2023 | markets.businessinsider.com
Opthea Appoints U.S.-Based Leadership with Fred Guerard as CEO and Peter Lang as CFO
October 23, 2023 | finance.yahoo.com
Retinal Vein Occlusion Market to Exhibit Considerable Growth at a CAGR of ~6% During the Study Period (2019–2032) | DelveInsight
September 25, 2023 | uk.finance.yahoo.com
Rising Glaucoma Cases Forecast a Strong Optic Nerves Disorder Treatment Market
September 13, 2023 | benzinga.com
Optic Nerves Disorder Treatment Market Rises: North America Takes the Helm
August 25, 2023 | time.com
Aerie Promo Codes
August 24, 2023 | uk.finance.yahoo.com
Angina Pectoris Drugs Global Market Report 2023
August 24, 2023 | uk.finance.yahoo.com
Ocular Hypertension Treatment Global Market Report 2023
July 18, 2023 | msn.com
Alcon (ALC) Gains From Robust Contact Lense Sales, Launches
June 27, 2023 | finance.yahoo.com
VillageMD Welcomes Richard Rubino as Chief Financial Officer
June 22, 2023 | marketwatch.com
The Glaucoma Therapeutics market's size, share, and revenue will be thoroughly examined, with an anticipated CAGR of 13% increase from 2023 to 2030.
June 22, 2023 | uk.finance.yahoo.com
I-Mab Announces the Appointment of Raj Kannan as CEO
June 22, 2023 | markets.businessinsider.com
I-Mab Names Raj Kannan CEO - Quick Facts
June 8, 2023 | uk.finance.yahoo.com
Ophthalmic Drugs Global Market Report 2023
See More Headlines
Receive AERI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aerie Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AERI
CUSIP
N/A
CIK
1337553
Web
www.aeriepharma.com
Phone
(919) 237-5300
Fax
949-526-8787
Employees
376
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.77)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-74,810,000.00
Net Margins
-17.09%
Pretax Margin
-16.47%
Return on Equity
N/A
Return on Assets
-2.00%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.27
Quick Ratio
1.92

Sales & Book Value

Annual Sales
$194.13 million
Price / Sales
3.88
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($3.32) per share
Price / Book
-4.59

Miscellaneous

Outstanding Shares
49,417,000
Free Float
47,223,000
Market Cap
$753.61 million
Optionable
Optionable
Beta
-0.06
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Raj Kannan (Age 58)
    CEO, Principal Financial Officer & Director
    Comp: $753.49k
  • Dr. Casey C. Kopczynski Ph.D. (Age 61)
    Co-Founder, Chief Innovation Officer & Head of Research and External Innovation
    Comp: $685.06k
  • Mr. John W. LaRocca Esq. (Age 57)
    Gen. Counsel & Sec.
    Comp: $676.62k
  • Mr. Peter F. Lang (Age 50)
    Chief Financial Officer
  • Dr. Michelle Senchyna Ph.D.
    Head of Clinical Devel. & Operations
  • Mr. Jeffrey M. Calabrese CPA (Age 55)
    VP of Fin. & Principal Accounting Officer
  • Ms. Carolyn McAuliffe
    Sr. Director of Communications
  • Ms. Wanda Francies
    Head of HR
  • Mr. Marvin J. Garrett (Age 71)
    Head of Regulatory Affairs & Quality Assurance
  • Mr. Craig R. Skenes
    Head of Bus. Devel.

Key Competitors

View All Competitors

AERI Stock Analysis - Frequently Asked Questions

How were Aerie Pharmaceuticals' earnings last quarter?

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.72) EPS for the quarter, missing analysts' consensus estimates of ($0.62) by $0.10. The business had revenue of $29.31 million for the quarter, compared to the consensus estimate of $29.13 million. During the same quarter in the previous year, the company posted ($0.65) EPS.

What other stocks do shareholders of Aerie Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aerie Pharmaceuticals investors own include Nicox (NICXF), Micron Technology (MU), Melinta Therapeutics (MLNT), BioMarin Pharmaceutical (BMRN), Gilead Sciences (GILD), Puma Biotechnology (PBYI), NVIDIA (NVDA), Wells Fargo & Company (WFC) and Alibaba Group (BABA).

This page (NASDAQ:AERI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
SHOCKING Crypto Leak…
Crypto 101 Media
The #1 Crypto for 2024
InvestorPlace
1970’s computer coder issues shocking A.I. warning
TradeSmith
How Biden has already won 2024
Porter & Company
Top 5 AI Stocks to Buy for 2024
Market Moving Trends